Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
17.12 USD | +2.42% | +2.95% | -45.45% |
Apr. 30 | UBS Adjusts ACADIA Pharmaceuticals' Price Target to $27 From $33, Keeps Buy Rating | MT |
Apr. 23 | Neuren Pharmaceuticals' Medication Secures Priority Review from Health Canada | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-45.45% | 2.76B | |
-0.38% | 42.19B | |
+44.30% | 40.15B | |
-6.20% | 28.31B | |
+5.15% | 24.63B | |
-24.20% | 18.2B | |
+26.31% | 12.01B | |
-3.64% | 11.76B | |
+12.65% | 10.4B | |
-3.47% | 9.94B |
- Stock Market
- Equities
- ACAD Stock
- News ACADIA Pharmaceuticals Inc.
- Sector Update: Health Care